TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nurix Therapeutics ( (NRIX) ) has issued an announcement.
On November 6, 2025, Nurix Therapeutics appointed Roger Dansey, M.D., to its board of directors and as a member of the Clinical and Commercialization Committee. Dr. Dansey, with a distinguished career in oncology and drug development, is expected to enhance the board’s expertise as Nurix advances its clinical trials and explores new treatments in protein degradation for cancer and autoimmune diseases.
The most recent analyst rating on (NRIX) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.
Spark’s Take on NRIX Stock
According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.
Nurix Therapeutics’ overall stock score is primarily impacted by its financial performance, which shows strong gross margins but significant profitability and cash flow challenges. Technical analysis indicates bullish momentum, though the stock may be overbought. Valuation is weak due to negative earnings and lack of dividends, highlighting the company’s ongoing financial struggles.
To see Spark’s full report on NRIX stock, click here.
More about Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, particularly for oncology and autoimmune diseases. The company is advancing a pipeline that includes degraders of Bruton’s tyrosine kinase and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, with collaborations involving major pharmaceutical companies like Gilead, Sanofi, and Pfizer.
Average Trading Volume: 1,272,918
Technical Sentiment Signal: Buy
Current Market Cap: $1.25B
See more insights into NRIX stock on TipRanks’ Stock Analysis page.